News
Patients
our commitments
We are committed to therapeutic progress to serve patient needs
We leverage our expertise to provide patients with medicines in over 130 countries. We focus our efforts on indications with significant medical need. Involving patients enables us to design suitable therapeutic solutions in each of our three therapeutic areas. We are committed to working with and for patients, day in, day out.
Focus on three key therapeutic areas
We are a world leading pharmaceutical group in cardiometabolism and the treatment of venous diseases. In oncology, we aim at using precision medicine with a transformative clinical benefit for cancer patients lives. We are also involved in neurology.
At Servier, we are moved by you, and we are moving with you.
According to Servier and Patient Advisory Councils we work with, Patient Engagement is “purposeful, timely collaboration where patients actively inform, shape, and co-create care, research, and innovation through ongoing dialogue that drives decisions, aligns with real needs, and builds lasting trust.”
We are listening.
You, patients across the world, are our guiding voices. We’ve embarked on a transformation, where you take a more active role in making decisions about your health. We aim to continue to evolve alongside you and mobilize the healthcare ecosystem in this direction. Why? You are the ones with the first-hand experience, the experts on how you live with your health condition.
Listening to your voices allows us to act with you and for you. We must be the ones moving with you.
News
Patient voices: Living with glioma
Read moreWe are acting with you.
By working with you, we will continue to leverage your insights to deliver therapeutic progress that genuinely meets your needs. At Servier, you are integral to every stage of the life cycle of our medicines, from the rarest therapeutic areas to the most common of diseases. You are a key stakeholder guiding the decisions we make together, either through our collaboration with small and large patient associations or through the creation of specialized patient advisory councils.
Our goal is to engage in dialogue with patient experts like you and ready to develop new treatments and health solutions at each step of the patient journey.
This mission is already in motion with:
We are committed to you.
Your voices inspire our commitments. By 2030, we at Servier pledge to having:
Genuine therapeutic progress comes through close collaboration with patients.
Top 10
Servier ranks into the top 10 (of 46 companies) by patient organizations working and/or familiar with the Servier Group*
1st
Ranked 1st out of 28 companies by oncology patient organizations*
177
patient organizations worked closely with Servier in 2024/2025
68%
of clinical trials protocols obtained patient feedback in 2024/2025
100%
of our lay summaries are approved by patient representatives and translated into the different languages of all the countries taking part in the study
100%
of Servier Group clinical trial participants’ informed consent documents were reviewed by patients in 2024/2025
* Enquête PatientView Report 2024 sur la réputation des entreprises pharmaceutiques
Leveraging industrial excellence and independence to serve patients
Thanks to our network of 13 production sites located throughout the world, we produce and distribute our medicines in accordance with the highest standards on quality, safety and reliability.
As a pharmaceutical Group deeply committed to health independence, we have always actively chosen to maintain significant production capacity in Europe. That is why we produce 96.1% of our active ingredients at our Oril Industrie facility in France, before distributing them to nine production sites for use in medicines prescribed in cardiology, neurology and diabetes.
Security and quality guarantee
96.1%
of our active ingredients produced at our Oril Industrie facility in France in 2024/2025.
By applying digital innovation across the entire value chain, we continue to enhance our ability to meet patient demand.
Combating counterfeit medicine
Counterfeit medicines represent a serious risk to public health and a danger to patients, as there can be a lack of active ingredients, incorrect dosage, impurities and toxic substances.
The WHO estimates that 10% of medicines distributed in developing countries are of substandard quality or are counterfeit. Counterfeit medicine therefore represents a major cause of inequalities in treatment.
We have been working for several decades to counter the scourge of counterfeit medicines.
As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), we promote prevention, training and medicine traceability.
In addition, our specialist teams are involved in developing innovative technology, such as electronic and near infrared product labeling which serve to analyze suspicious boxes of medicines found throughout the world. More generally, our generic medicines help combat the problem posed by falsified medicines; as generics are less expensive than brand-name medicines, they help drive counterfeit drugs off the market.
As a member of the Anti-Counterfeit Group within the European Federation of Pharmaceutical Industries and Associations, we take steps to enhance prevention, training and medicine traceability.
We have put together a dedicated team to combat counterfeit medicine, based in France and China.
We take steps to improve medicine traceability, for example by printing unique serial numbers on boxes as well as measures to guarantee security and authenticity. We also provide authorities with training and organize awareness campaigns to combat counterfeit medicines.
The Group manufactures generic medicines covering the majority of illnesses. As generics are less expensive than brand-name medicines, they help drive counterfeit drugs off the market.